Tezspire 210 mg solution for injection in pre-filled syringe
D5180C00047
Phase 3 small_molecule active
Quick answer
Tezspire 210 mg solution for injection in pre-filled syringe for Severe Asthma is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Severe Asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active